What is VYNE Therapeutics' operating income?

VYNE Therapeutics' total operating income in 2025 was -$29.75 million, based on the following breakdown: Total Gross Profit: $570 thousand Total Operating Expenses: $30.32 million

VYNE Therapeutics (VYNE) Financials

$0.76 -0.01 (-0.85%)

Closing price 07/17/2026 04:00 PM Eastern

Extended Trading

$0.76 0.00 (-0.39%)

As of 07/17/2026 07:59 PM Eastern

Compare

Annual Income Statements for VYNE Therapeutics

This table shows VYNE Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Income / (Loss) Attributable to Common Shareholders	-4.61	-14	-29	-76	-98	-256	-73	-23	-28	-40	-26
Consolidated Net Income / (Loss)	-4.61	-14	-29	-74	-95	-256	-73	-23	-28	-40	-26
Net Income / (Loss) Continuing Operations	-4.61	-14	-29	-76	-98	-254	-44	-34	-28	-40	-27
Total Pre-Tax Income	-4.61	-14	-30	-74	-95	-256	-45	-34	-28	-40	-27
Total Operating Income	-4.61	-14	-30	-75	-96	-253	-39	-34	-29	-44	-30
Total Gross Profit	0.00	0.67	4.58	3.60	0.44	20	0.93	0.48	0.42	0.50	0.57
Total Revenue	0.00	0.67	4.58	3.60	0.44	21	0.93	0.48	0.42	0.50	0.57
Operating Revenue	0.00	0.67	4.58	3.60	0.44	21	0.93	0.48	0.42	0.50	0.57
Total Cost of Revenue	0.00	0.00	0.00	0.00	0.00	1.39	0.00	0.00	0.00	0.00	0.00
Total Operating Expenses	4.61	15	34	78	96	272	40	35	30	44	30
Selling, General & Admin Expense	1.69	3.75	5.17	14	45	90	20	16	13	13	11
Research & Development Expense	2.92	11	29	64	51	44	20	18	16	31	19
Total Other Income / (Expense), net	0.00	0.00	0.00	-0.94	-2.36	-4.39	-5.75	0.36	1.39	3.83	3.02
Other Income / (Expense), net	-	-	-	0.94	1.44	-	-0.14	0.36	1.39	3.83	3.02
Income Tax Expense	-	-	-	0.21	-0.18	-0.26	-0.45	0.01	0.00	0.00	0.00
Net Income / (Loss) Discontinued Operations	-	-	-	-	-	-	-29	11	-0.58	-0.03	0.25
Basic Earnings per Share	($0.97)	($2.82)	($5.69)	$11.47	$11.22	$7.88	($25.64)	($7.28)	($2.78)	($0.93)	($0.62)
Weighted Average Basic Shares Outstanding	4.74M	4.99M	5.11M	6.47M	8.49M	32.42M	2.86M	3.19M	10.27M	42.59M	42.77M
Diluted Earnings per Share	($0.97)	($2.82)	($5.69)	$11.47	$11.22	$7.88	($25.64)	($7.28)	($2.78)	($0.93)	($0.62)
Weighted Average Diluted Shares Outstanding	4.74M	4.99M	5.11M	6.47M	8.49M	32.42M	2.86M	3.19M	10.27M	42.59M	42.77M
Weighted Average Basic & Diluted Shares Outstanding	4.74M	4.99M	5.11M	6.47M	8.49M	32.42M	56.17M	3.26M	14.10M	15.21M	33.32M

This table shows VYNE Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	3/31/2026
Net Income / (Loss) Attributable to Common Shareholders	-6.58	-6.19	-6.25	-9.41	-12	-12	-8.61	-5.76	-3.59
Consolidated Net Income / (Loss)	-6.58	-6.19	-6.25	-9.41	-12	-12	-8.61	-5.76	-3.59
Net Income / (Loss) Continuing Operations	-6.07	-6.15	-6.24	-9.40	-12	-12	-8.60	-5.75	-3.59
Total Pre-Tax Income	-6.07	-6.15	-6.24	-9.40	-12	-12	-8.60	-5.75	-3.59
Total Operating Income	-6.23	-6.83	-7.38	-10	-13	-13	-9.20	-7.54	-3.82
Total Gross Profit	0.11	0.08	0.10	0.20	0.12	0.08	0.20	0.07	0.09
Total Revenue	0.11	0.08	0.10	0.20	0.12	0.08	0.20	0.07	0.09
Operating Revenue	0.11	0.08	0.10	0.20	0.12	0.08	0.20	0.07	0.09
Total Cost of Revenue	0.00	-	0.00	0.00	0.00	-	0.00	0.00	0.00
Total Operating Expenses	6.35	6.91	7.48	11	13	13	9.40	7.61	3.90
Selling, General & Admin Expense	3.03	3.89	3.77	3.29	2.96	3.17	3.28	2.73	3.09
Research & Development Expense	3.32	3.02	3.71	7.31	10	9.68	6.12	4.88	0.82
Total Other Income / (Expense), net	0.16	0.68	1.14	1.00	0.93	0.76	0.59	1.80	0.23
Other Income / (Expense), net	0.16	0.68	1.14	1.00	0.93	0.76	0.59	1.80	0.23
Income Tax Expense	0.00	-	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Income / (Loss) Discontinued Operations	-0.51	-0.04	-0.01	-0.01	0.00	-0.01	-0.01	-0.01	0.00
Basic Earnings per Share	($2.01)	($0.60)	($0.15)	($0.22)	($0.29)	($0.28)	($0.20)	($0.13)	($0.08)
Weighted Average Basic Shares Outstanding	3.28M	10.27M	42.58M	42.59M	42.59M	42.59M	42.67M	42.76M	42.77M
Diluted Earnings per Share	($2.01)	($0.60)	($0.15)	($0.22)	($0.29)	($0.28)	($0.20)	($0.13)	($0.08)
Weighted Average Diluted Shares Outstanding	3.28M	10.27M	42.58M	42.59M	42.59M	42.59M	42.67M	42.76M	42.77M
Weighted Average Basic & Diluted Shares Outstanding	13.96M	14.10M	14.53M	14.75M	14.75M	15.21M	16.66M	25.47M	33.35M

This table details how cash moves in and out of VYNE Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Change in Cash & Equivalents	44	-40	6.18	12	16	14	-16	-12	-0.30	-11	4.10
Net Cash From Operating Activities	-4.18	-2.27	-28	-69	-73	-137	-56	-29	-25	-34	-33
Net Cash From Continuing Operating Activities	-4.18	-2.27	-28	-69	-73	-137	-56	-29	-25	-34	-33
Net Income / (Loss) Continuing Operations	-4.61	-14	-29	-74	-95	-256	-73	-23	-28	-40	-26
Consolidated Net Income / (Loss)	-4.61	-14	-29	-74	-95	-256	-73	-23	-28	-40	-26
Depreciation Expense	0.00	0.00	0.01	0.32	0.35	0.34	0.11	0.07	0.00	0.00	0.02
Amortization Expense	0.00	0.16	0.07	-	-	-	-	0.00	-0.26	-2.44	-0.78
Non-Cash Adjustments To Reconcile Net Income	0.04	0.57	1.47	4.96	4.75	158	12	-8.34	3.52	3.19	2.31
Changes in Operating Assets and Liabilities, net	0.38	11	-0.69	0.29	17	-40	4.78	2.28	-0.15	5.11	-8.19
Net Cash From Investing Activities	0.00	-38	-15	-12	42	89	1.03	16	-57	23	37
Net Cash From Continuing Investing Activities	0.00	-38	-15	-12	42	89	1.03	16	-57	23	37
Purchase of Property, Plant & Equipment	0.00	-0.03	-0.03	-0.57	-1.06	-0.11	-	-	0.00	-0.12	0.00
Purchase of Investments	0.00	-55	-64	-78	-45	-	-	0.00	-62	-61	-31
Sale and/or Maturity of Investments	0.00	18	49	66	88	51	1.03	-	0.00	84	68
Net Cash From Financing Activities	48	0.00	49	92	48	62	40	1.65	82	-0.14	-0.14
Net Cash From Continuing Financing Activities	48	0.00	49	92	48	62	40	1.65	82	-0.14	-0.14
Other Financing Activities, net	0.10	0.00	0.03	0.89	0.40	0.17	0.23	-0.03	-0.07	-0.14	-0.14

This table details how cash moves in and out of VYNE Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	3/31/2026
Net Change in Cash & Equivalents	-5.20	15	-12	11	-13	3.61	8.28	-6.16	0.60
Net Cash From Operating Activities	-5.15	-5.14	-7.98	-8.48	-8.51	-9.00	-11	-11	-4.08
Net Cash From Continuing Operating Activities	-5.15	-5.14	-7.98	-8.48	-8.51	-9.00	-11	-11	-4.08
Net Income / (Loss) Continuing Operations	-6.58	-6.19	-6.25	-9.41	-12	-12	-8.61	-5.76	-3.59
Consolidated Net Income / (Loss)	-6.58	-6.19	-6.25	-9.41	-12	-12	-8.61	-5.76	-3.59
Depreciation Expense	-	-	0.00	-	-	-	0.01	0.01	0.01
Amortization Expense	-	-0.26	-0.78	-0.62	-0.51	-0.54	-0.32	-0.21	-0.02
Non-Cash Adjustments To Reconcile Net Income	0.86	0.93	0.98	0.89	0.74	0.58	0.76	0.53	0.47
Changes in Operating Assets and Liabilities, net	0.57	0.38	-1.94	0.66	3.42	2.98	-3.30	-5.37	-0.96
Net Cash From Investing Activities	-	-62	-3.57	19	-4.82	13	20	4.68	4.70
Net Cash From Continuing Investing Activities	-	-62	-3.57	19	-4.82	13	20	4.68	4.70
Purchase of Investments	-	-62	-15	-6.88	-28	-10	-14	-9.58	0.00
Sale and/or Maturity of Investments	-	-	12	26	24	23	34	14	4.70
Net Cash From Financing Activities	-0.05	83	-0.01	-0.00	-0.00	-0.13	-0.09	-0.03	-0.02
Net Cash From Continuing Financing Activities	-0.05	83	-0.01	-0.00	-0.00	-0.13	-0.09	-0.03	-0.02
Other Financing Activities, net	-0.05	-0.00	-0.01	-0.00	-0.00	-0.13	-0.09	-0.03	-0.02

This table presents VYNE Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Total Assets	42	67	140	81	94	67	41	98	67	30
Total Current Assets	32	64	140	76	87	63	38	96	64	30
Cash & Equivalents	4.03	10	50	44	58	42	31	31	20	24
Short-Term Investments	27	49	87	28	1.03	-	0.00	63	42	4.98
Prepaid Expenses	0.63	3.57	3.25	1.56	4.59	4.57	2.30	2.66	2.92	1.00
Plant, Property, & Equipment, net	0.03	0.03	0.15	2.89	0.56	0.35	0.00	0.00	0.11	0.09
Total Noncurrent Assets	10	2.98	0.28	1.86	5.93	3.51	2.48	1.72	2.36	0.06
Other Noncurrent Operating Assets	0.07	-	0.28	1.86	5.93	3.51	2.48	1.72	2.36	0.06
Total Liabilities & Shareholders' Equity	42	67	140	81	94	67	41	98	67	30
Total Liabilities	12	15	9.55	64	56	18	9.35	8.95	15	2.40
Total Current Liabilities	3.90	7.82	9.54	29	22	18	9.35	7.54	15	2.40
Accounts Payable	1.53	2.46	3.29	19	4.78	6.51	2.39	1.66	2.71	1.04
Accrued Expenses	0.58	3.56	6.25	3.38	11	8.59	4.38	4.12	9.27	0.94
Current Employee Benefit Liabilities	-	-	-	5.23	4.67	2.75	2.58	1.65	1.43	0.41
Total Noncurrent Liabilities	8.59	6.76	0.01	34	34	0.21	0.00	1.41	0.00	0.00
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	-29	-57	130	18	37	49	31	89	52	28
Total Preferred & Common Equity	-29	-57	130	18	37	49	31	89	52	28
Preferred Stock	-	0.00	0.00	0.00	0.00	-	0.00	0.00	0.00	0.00
Total Common Equity	-29	-57	130	18	37	49	31	89	52	28
Common Stock	0.70	2.21	241	328	604	688	694	780	783	785
Retained Earnings	-30	-59	-111	-311	-566	-640	-663	-691	-731	-758
Accumulated Other Comprehensive Income / (Loss)	-0.03	-0.05	-0.10	0.01	0.00	-	0.00	0.03	0.02	0.00

This table presents VYNE Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2023	Q1 2024	Q2 2024	Q3 2024	Q1 2025	Q2 2025	Q1 2026
Period end date	9/30/2023	3/31/2024	6/30/2024	9/30/2024	3/31/2025	6/30/2025	3/31/2026
Total Assets	19	92	87	76	56	45	26
Total Current Assets	18	90	84	74	55	44	26
Cash & Equivalents	15	19	30	16	28	22	25
Short-Term Investments	-	67	48	54	22	18	0.30
Prepaid Expenses	1.76	4.22	5.63	3.30	4.64	4.70	0.86
Plant, Property, & Equipment, net	0.00	0.00	0.00	0.00	0.11	0.10	0.08
Total Noncurrent Assets	1.76	1.45	2.87	2.66	1.40	0.27	0.00
Other Noncurrent Operating Assets	1.76	1.45	2.87	2.66	1.40	0.27	0.00
Total Liabilities & Shareholders' Equity	19	92	87	76	56	45	26
Total Liabilities	7.76	8.31	12	13	12	5.84	1.24
Total Current Liabilities	6.45	6.93	12	13	12	5.84	1.24
Accounts Payable	0.72	2.80	4.52	3.99	3.53	1.41	0.26
Accrued Expenses	4.45	3.64	5.07	6.17	6.86	3.58	0.89
Current Employee Benefit Liabilities	1.28	0.38	0.74	1.07	0.52	0.82	0.09
Total Noncurrent Liabilities	1.31	1.38	0.03	0.00	0.00	0.00	0.00
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	12	83	75	64	44	39	25
Total Preferred & Common Equity	12	83	75	64	44	39	25
Preferred Stock	-	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	12	83	75	64	44	39	25
Common Stock	697	781	782	783	784	784	786
Retained Earnings	-685	-698	-707	-719	-740	-746	-761
Accumulated Other Comprehensive Income / (Loss)	-	-0.07	-0.06	0.03	0.00	-0.00	0.00

This table displays calculated financial ratios and metrics derived from VYNE Therapeutics' official financial filings.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	0.00%	0.00%	579.82%	-21.54%	-87.68%	4,638.83%	-95.57%	-48.76%	-11.11%	18.16%	13.77%
EBITDA Growth	0.00%	-207.51%	-108.32%	-149.44%	-27.77%	-168.07%	84.56%	13.04%	16.93%	-50.18%	34.93%
EBIT Growth	0.00%	-211.02%	-106.48%	-149.89%	-27.70%	-167.43%	84.54%	13.10%	17.86%	-42.81%	32.84%
NOPAT Growth	0.00%	-211.02%	-106.48%	-153.07%	-28.02%	-163.42%	84.59%	11.86%	14.69%	-49.15%	31.83%
Net Income Growth	0.00%	-205.30%	-106.68%	-155.07%	-28.34%	-168.52%	71.31%	68.35%	-22.59%	-40.00%	33.52%
EPS Growth	0.00%	-190.72%	-101.77%	-155.07%	-28.34%	-168.52%	71.31%	68.35%	61.81%	66.55%	33.33%
Operating Cash Flow Growth	0.00%	45.85%	-1,146.00%	-143.30%	-6.89%	-86.78%	58.88%	48.20%	13.22%	-34.06%	2.50%
Free Cash Flow Firm Growth	0.00%	0.00%	-1,386.06%	-154.48%	12.02%	-322.83%	93.39%	-90.00%	41.64%	-66.04%	-12.94%
Invested Capital Growth	0.00%	0.00%	13.43%	42.34%	-292.75%	148.65%	-118.39%	121.22%	-1,143.84%	-106.26%	86.82%
Revenue Q/Q Growth	0.00%	0.00%	0.00%	-73.20%	106.58%	24.65%	-81.17%	-35.89%	19.77%	1.62%	0.00%
EBITDA Q/Q Growth	0.00%	0.00%	0.00%	-59.66%	2.68%	4.85%	24.96%	2.99%	4.55%	-17.02%	0.00%
EBIT Q/Q Growth	0.00%	0.00%	0.00%	-62.27%	2.89%	4.84%	24.99%	3.48%	5.42%	-17.26%	0.00%
NOPAT Q/Q Growth	0.00%	0.00%	0.00%	-64.33%	1.40%	5.76%	25.25%	2.45%	3.79%	-15.75%	0.00%
Net Income Q/Q Growth	0.00%	0.00%	0.00%	-71.96%	2.55%	5.42%	13.67%	6.54%	11.66%	-17.16%	0.00%
EPS Q/Q Growth	0.00%	0.00%	0.00%	-71.96%	2.55%	5.42%	13.67%	6.54%	71.66%	-16.25%	0.00%
Operating Cash Flow Q/Q Growth	0.00%	0.00%	0.00%	-48.39%	12.31%	-2.34%	21.41%	15.13%	-1.30%	-12.83%	0.00%
Free Cash Flow Firm Q/Q Growth	0.00%	0.00%	0.00%	0.00%	26.03%	-5.73%	62.02%	-14.63%	-20.88%	-8.43%	0.00%
Invested Capital Q/Q Growth	0.00%	0.00%	0.00%	-1.73%	-262.79%	97.71%	-134.54%	-90.25%	-14.39%	-40.85%	0.00%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	0.00%	100.00%	100.00%	100.00%	100.00%	93.37%	100.00%	100.00%	100.00%	100.00%	100.00%
EBITDA Margin	0.00%	-2,102.37%	-644.24%	-2,048.18%	-21,237.70%	-1,201.38%	-4,182.28%	-7,098.53%	-6,633.73%	-8,431.54%	-4,822.28%
Operating Margin	0.00%	-2,126.41%	-645.85%	-2,083.23%	-21,641.76%	-1,203.00%	-4,179.48%	-7,189.73%	-6,900.47%	-8,709.98%	-5,219.12%
EBIT Margin	0.00%	-2,126.41%	-645.85%	-2,057.05%	-21,316.70%	-1,203.00%	-4,193.99%	-7,113.63%	-6,573.58%	-7,944.71%	-4,689.82%
Profit (Net Income) Margin	0.00%	-2,087.24%	-634.57%	-2,062.95%	-21,484.88%	-1,217.40%	-7,876.37%	-4,865.83%	-6,710.38%	-7,950.90%	-4,646.14%
Tax Burden Percent	100.00%	98.16%	98.25%	100.29%	99.82%	99.90%	164.21%	68.40%	102.08%	100.08%	99.07%
Interest Burden Percent	100.00%	100.00%	100.00%	100.00%	100.98%	101.30%	114.37%	100.00%	100.00%	100.00%	100.00%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-594.84%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-475.08%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	424.56%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	0.00%	-47.59%	-71.04%	-81.20%	-128.66%	-928.19%	-170.28%	-57.99%	-47.36%	-56.57%	-66.33%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	-1,880.86%	0.00%	-6,052.17%	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	0.00%	-34.08%	-54.34%	-71.52%	-85.43%	-288.79%	-48.57%	-62.95%	-40.26%	-48.37%	-55.08%
Return on Assets (ROA)	0.00%	-33.45%	-53.39%	-71.73%	-86.10%	-292.24%	-91.21%	-43.06%	-41.10%	-48.40%	-54.57%
Return on Common Equity (ROCE)	0.00%	47.39%	75.05%	-32.60%	-128.66%	-928.19%	-170.28%	-57.84%	-47.28%	-56.57%	-66.33%
Return on Equity Simple (ROE_SIMPLE)	0.00%	47.78%	50.98%	-56.88%	-541.55%	-681.64%	-150.77%	-74.39%	-32.06%	0.00%	0.00%
Net Operating Profit after Tax (NOPAT)	-3.23	-10	-21	-52	-67	-177	-27	-24	-20	-31	-21
NOPAT Margin	0.00%	-1,488.49%	-452.10%	-1,458.26%	-15,149.23%	-842.10%	-2,925.64%	-5,032.81%	-4,830.33%	-6,096.99%	-3,653.39%
Net Nonoperating Expense Percent (NNEP)	0.00%	-19.53%	-16.11%	-21.88%	-31.73%	-235.49%	-119.76%	1.95%	-12.83%	-12.00%	-12.50%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	-	-	-	-23.08%	-58.65%	-75.00%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	6.63%	0.00%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	0.00%	556.53%	112.79%	389.79%	10,183.75%	426.54%	2,180.34%	3,435.43%	3,154.48%	2,633.13%	1,944.21%
R&D to Revenue	0.00%	1,669.88%	633.06%	1,793.44%	11,558.01%	207.37%	2,099.14%	3,854.30%	3,845.99%	6,176.85%	3,374.91%
Operating Expenses to Revenue	0.00%	2,226.41%	745.85%	2,183.23%	21,741.76%	1,296.37%	4,279.48%	7,289.73%	7,000.47%	8,809.98%	5,319.12%
Earnings before Interest and Taxes (EBIT)	-4.61	-14	-30	-74	-94	-253	-39	-34	-28	-40	-27
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-4.61	-14	-30	-74	-94	-252	-39	-34	-28	-42	-27
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	0.00	0.00	0.00	0.73	6.33	7.07	1.12	0.28	0.37	0.95	0.53
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	0.73	6.33	7.07	1.12	0.28	0.37	0.95	0.53
Price to Revenue (P/Rev)	0.00	176.56	25.97	26.62	251.21	12.64	58.63	18.25	76.70	98.64	25.92
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	0.00	0.00	21.30	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	0.00	202.78	36.20	0.00	159.47	11.38	12.60	0.00	0.00	0.00	0.00
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	78.84	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	1.86	0.88	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	1.86	0.88	0.00	0.00	0.00	0.00	0.00
Financial Leverage	0.00	-1.40	-1.27	-1.09	-1.20	-1.22	-0.89	-1.02	-1.03	-1.10	-1.13
Leverage Ratio	0.00	1.42	1.33	1.13	1.49	3.18	1.87	1.35	1.15	1.17	1.22
Compound Leverage Factor	0.00	1.42	1.33	1.13	1.51	3.22	2.14	1.35	1.15	1.17	1.22
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	65.06%	46.94%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	65.06%	46.94%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	199.59%	209.07%	0.00%	0.00%	0.00%	0.00%	0.67%	0.00%	0.00%	0.00%
Common Equity to Total Capital	0.00%	-99.59%	-109.07%	100.00%	34.94%	53.06%	100.00%	99.33%	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	0.00	0.00	0.00	-0.35	-0.13	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00	0.00	0.43	0.10	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	-0.35	-0.13	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00	0.00	-0.49	-0.19	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00	0.00	0.61	0.15	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	-0.49	-0.19	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	0.00	4.39	3.27	4.30	-7.45	-13.45	-12.68	-24.09	-7.58	-14.36	-33.28
Noncontrolling Interest Sharing Ratio	0.00%	199.59%	205.64%	59.85%	0.00%	0.00%	0.00%	0.26%	0.18%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	0.00	8.08	8.17	14.62	2.61	4.01	3.47	4.10	12.73	4.35	12.53
Quick Ratio	0.00	7.92	7.71	14.28	2.46	3.42	2.74	3.31	12.37	4.15	12.11
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	0.00	1.73	-22	-57	-50	-211	-14	-27	-15	-26	-29
Operating Cash Flow to CapEx	0.00%	-7,306.45%	-104,525.93%	-12,327.47%	-7,209.63%	-121,311.50%	0.00%	0.00%	0.00%	-29,035.90%	0.00%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	-54.20	-48.08	-2.49	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	-79.69	-31.23	-10.05	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	-80.79	-31.25	-10.05	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.00	0.02	0.08	0.03	0.00	0.24	0.01	0.01	0.01	0.01	0.01
Accounts Receivable Turnover	0.00	0.00	0.00	0.00	0.00	2.63	0.08	0.00	0.00	0.00	0.00
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.32	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	0.00	24.96	166.62	41.32	0.29	12.21	2.05	0.00	0.00	0.00	5.62
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00	0.12	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	0.00	0.00	0.00	0.00	0.00	138.69	4,587.40	0.00	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	1,148.49	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00	3,163.86	0.00	0.00	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	0.00	0.00	0.00	0.00	0.00	-1,876.67	4,587.40	0.00	0.00	0.00	0.00
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	0.00	-12	-10	-5.87	-23	11	-2.06	0.44	-4.57	-9.43	-1.24
Invested Capital Turnover	0.00	-0.11	-0.42	-0.45	-0.03	-3.54	0.20	-0.59	-0.21	-0.07	-0.11
Increase / (Decrease) in Invested Capital	0.00	-12	1.58	4.31	-17	34	-13	2.50	-5.01	-4.86	8.19
Enterprise Value (EV)	0.00	137	166	-41	71	239	12	-22	-61	-12	-14
Market Capitalization	119	119	119	96	111	265	55	8.71	33	49	15
Book Value per Share	$0.00	($5.90)	($11.17)	$5.61	$0.73	$0.22	$0.91	$0.54	$6.36	$3.53	$1.09
Tangible Book Value per Share	$0.00	($5.90)	($11.17)	$5.61	$0.73	$0.22	$0.91	$0.54	$6.36	$3.53	$1.09
Total Capital	0.00	30	52	130	50	71	49	31	89	52	28
Total Debt	0.00	0.00	0.00	0.00	33	33	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	33	33	0.00	0.00	0.00	0.00	0.00
Net Debt	0.00	-41	-62	-136	-41	-26	-43	-31	-93	-62	-29
Capital Expenditures (CapEx)	0.00	0.03	0.03	0.56	1.02	0.11	0.00	0.00	0.00	0.12	0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)	0.00	-3.27	-3.46	-6.29	-26	6.05	2.13	-2.05	-4.88	-12	-1.39
Debt-free Net Working Capital (DFNWC)	0.00	28	56	130	47	65	45	29	88	50	28
Net Working Capital (NWC)	0.00	28	56	130	47	65	45	29	88	50	28
Net Nonoperating Expense (NNE)	1.38	4.04	8.36	22	28	79	46	-0.80	7.97	9.29	5.66
Net Nonoperating Obligations (NNO)	0.00	-41	-62	-136	-41	-26	-51	-31	-93	-62	-29
Total Depreciation and Amortization (D&A)	0.00	0.16	0.07	0.32	0.35	0.34	0.11	0.07	-0.26	-2.44	-0.76
Debt-free, Cash-free Net Working Capital to Revenue	0.00%	-485.31%	-75.45%	-175.08%	-5,931.83%	28.81%	228.46%	-428.72%	-1,151.42%	-2,374.85%	-244.39%
Debt-free Net Working Capital to Revenue	0.00%	4,100.45%	1,223.13%	3,614.91%	10,629.35%	311.98%	4,831.58%	6,064.99%	20,854.95%	9,903.79%	4,844.74%
Net Working Capital to Revenue	0.00%	4,100.45%	1,223.13%	3,614.91%	10,629.35%	311.98%	4,831.58%	6,064.99%	20,854.95%	9,903.79%	4,844.74%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($69.84)	($203.04)	($409.68)	($170.64)	($222.48)	$141.84	$25.56	($7.28)	($2.78)	($0.93)	($0.62)
Adjusted Weighted Average Basic Shares Outstanding	65.77K	69.27K	319.14K	323.03K	339.43K	2.85M	2.86M	3.19M	10.27M	42.59M	42.77M
Adjusted Diluted Earnings per Share	($69.84)	($203.04)	($409.68)	($170.64)	($222.48)	$141.84	$25.56	($7.28)	($2.78)	($0.93)	($0.62)
Adjusted Weighted Average Diluted Shares Outstanding	65.77K	69.27K	319.14K	323.03K	339.43K	2.85M	2.86M	3.19M	10.27M	42.59M	42.77M
Adjusted Basic & Diluted Earnings per Share	($69.84)	($203.04)	($409.68)	($170.64)	($222.48)	$141.84	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	65.77K	69.27K	70.95K	300.95K	330.82K	1.80M	3.12M	3.26M	14.10M	15.21M	33.32M
Normalized Net Operating Profit after Tax (NOPAT)	-3.23	-10	-21	-52	-67	-139	-27	-24	-20	-31	-21
Normalized NOPAT Margin	0.00%	-1,488.49%	-452.10%	-1,458.26%	-15,149.23%	-660.89%	-2,925.64%	-5,032.81%	-4,830.33%	-6,096.99%	-3,653.39%
Pre Tax Income Margin	0.00%	-2,126.41%	-645.85%	-2,057.05%	-21,524.61%	-1,218.63%	-4,796.56%	-7,113.63%	-6,573.58%	-7,944.71%	-4,689.82%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	-102.53	-57.53	-6.96	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	-72.87	-40.27	-4.86	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	-103.64	-57.55	-6.96	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	-73.97	-40.30	-4.86	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from VYNE Therapeutics' official financial filings.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	3/31/2026
DEI Shares Outstanding	3,279,971.00	13,957,324.00	14,098,888.00	14,528,247.00	14,749,397.00	14,751,433.00	15,209,862.00	16,664,892.00	33,323,171.00
DEI Adjusted Shares Outstanding	3,279,971.00	13,957,324.00	14,098,888.00	14,528,247.00	14,749,397.00	14,751,433.00	15,209,862.00	16,664,892.00	33,323,171.00
DEI Earnings Per Adjusted Shares Outstanding	-2.01	-0.44	-0.44	-0.65	-0.82	-0.82	-0.57	-0.35	-0.11
Growth Metrics	-	-	-	-	-	-	-	-	-
Revenue Growth	-31.74%	1,166.67%	-1.01%	46.67%	6.14%	10.53%	106.12%	-65.15%	-57.43%
EBITDA Growth	33.17%	18.94%	-25.05%	0.27%	-108.58%	-95.97%	-27.12%	40.52%	59.68%
EBIT Growth	34.40%	20.61%	-11.21%	6.41%	-100.25%	-95.25%	-37.85%	38.83%	58.33%
NOPAT Growth	33.20%	14.44%	-25.62%	-0.76%	-109.99%	-86.94%	-24.62%	27.45%	58.51%
Net Income Growth	30.39%	37.78%	-11.15%	6.48%	-84.64%	-94.28%	-37.80%	38.82%	58.37%
EPS Growth	31.63%	80.77%	91.38%	92.88%	85.57%	53.33%	-33.33%	40.91%	60.00%
Operating Cash Flow Growth	27.69%	-6.78%	-45.69%	11.41%	-65.18%	-75.18%	-43.60%	-27.36%	64.39%
Free Cash Flow Firm Growth	181.69%	102.82%	-246.10%	-524.61%	-256.74%	-1,887.56%	54.05%	-4.90%	-190.60%
Invested Capital Growth	-188.98%	-1,143.84%	31.57%	4.40%	-67.50%	-106.26%	-133.11%	76.66%	95.26%
Revenue Q/Q Growth	-15.56%	-33.33%	28.95%	102.04%	-38.89%	-30.58%	140.48%	-65.84%	0.00%
EBITDA Q/Q Growth	39.52%	-5.52%	-9.55%	-42.65%	-26.49%	0.86%	28.94%	33.25%	0.00%
EBIT Q/Q Growth	39.52%	-1.32%	-1.46%	-50.54%	-29.40%	1.21%	28.37%	33.20%	0.00%
NOPAT Q/Q Growth	39.58%	-9.58%	-8.04%	-40.87%	-25.92%	2.45%	27.98%	18.00%	0.00%
Net Income Q/Q Growth	34.54%	6.01%	-0.99%	-50.52%	-29.25%	1.11%	28.37%	33.17%	0.00%
EPS Q/Q Growth	34.95%	70.15%	75.00%	-46.67%	-31.82%	3.45%	28.57%	35.00%	0.00%
Operating Cash Flow Q/Q Growth	46.19%	0.29%	-55.36%	-6.28%	-0.34%	-5.75%	-27.36%	5.74%	0.00%
Free Cash Flow Firm Q/Q Growth	135.81%	-94.47%	-2,895.01%	-16.41%	12.96%	36.88%	28.16%	-165.78%	0.00%
Invested Capital Q/Q Growth	-16.56%	-14.39%	42.39%	-24.45%	-104.24%	-40.85%	34.89%	87.54%	0.00%
Profitability Metrics	-	-	-	-	-	-	-	-	-
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
EBITDA Margin	-5,325.44%	-8,428.95%	-7,161.22%	-5,056.06%	-10,465.29%	-14,945.24%	-4,416.34%	-8,630.43%	-4,182.56%
Operating Margin	-5,468.42%	-8,988.16%	-7,530.61%	-5,250.51%	-10,819.01%	-15,202.38%	-4,552.97%	-10,930.43%	-4,437.21%
EBIT Margin	-5,325.44%	-8,093.42%	-6,368.37%	-4,744.95%	-10,047.11%	-14,297.62%	-4,258.91%	-8,328.99%	-4,168.60%
Profit (Net Income) Margin	-5,775.44%	-8,142.11%	-6,376.53%	-4,750.51%	-10,047.11%	-14,311.90%	-4,262.87%	-8,340.58%	-4,168.60%
Tax Burden Percent	108.45%	100.60%	100.13%	100.12%	100.00%	100.10%	100.09%	100.14%	100.00%
Interest Burden Percent	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-5,475.05%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	-5,466.36%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	5,413.89%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	-61.16%	-47.36%	-52.97%	-61.70%	-90.62%	-56.57%	-66.19%	-67.77%	-62.40%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	-56.98%	-49.57%	-42.44%	-41.32%	-103.77%	-87.04%	-34.80%	-60.36%	-45.99%
Return on Assets (ROA)	-61.79%	-49.87%	-42.50%	-41.37%	-103.77%	-87.13%	-34.83%	-60.44%	-45.99%
Return on Common Equity (ROCE)	-61.16%	-47.28%	-52.97%	-61.70%	-90.62%	-56.57%	-66.19%	-67.77%	-62.40%
Return on Equity Simple (ROE_SIMPLE)	-279.96%	0.00%	-34.88%	0.00%	-53.51%	0.00%	0.00%	0.00%	0.00%
Net Operating Profit after Tax (NOPAT)	-4.36	-4.78	-5.17	-7.28	-9.16	-8.94	-6.44	-5.28	-2.67
NOPAT Margin	-3,827.89%	-6,291.71%	-5,271.43%	-3,675.35%	-7,573.31%	-10,641.67%	-3,187.08%	-7,651.30%	-3,106.05%
Net Nonoperating Expense Percent (NNEP)	-8.69%	-2.26%	-1.86%	-4.31%	-6.98%	-3.98%	-3.19%	-0.81%	-2.43%
Return On Investment Capital (ROIC_SIMPLE)	-	-5.39%	-6.20%	-9.72%	-	-17.16%	-14.59%	-13.58%	-10.84%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	2,657.89%	5,111.84%	3,846.94%	1,660.61%	2,449.59%	3,773.81%	1,621.29%	3,956.52%	3,587.21%
R&D to Revenue	2,910.53%	3,976.32%	3,783.67%	3,689.90%	8,469.42%	11,528.57%	3,031.68%	7,073.91%	950.00%
Operating Expenses to Revenue	5,568.42%	9,088.16%	7,630.61%	5,350.51%	10,919.01%	15,302.38%	4,652.97%	11,030.43%	4,537.21%
Earnings before Interest and Taxes (EBIT)	-6.07	-6.15	-6.24	-9.40	-12	-12	-8.60	-5.75	-3.59
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-6.07	-6.41	-7.02	-10	-13	-13	-8.92	-5.96	-3.60
Valuation Ratios	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	1.15	0.37	0.52	0.38	0.44	0.95	0.54	0.71	0.81
Price to Tangible Book Value (P/TBV)	1.15	0.37	0.52	0.38	0.44	0.95	0.54	0.71	0.81
Price to Revenue (P/Rev)	37.43	76.70	102.33	58.89	56.25	98.64	39.72	57.77	43.86
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-0.99	-1.03	-1.06	-1.07	-1.14	-1.10	-1.07	-1.04	-1.09
Leverage Ratio	1.28	1.15	1.16	1.21	1.27	1.17	1.16	1.15	1.20
Compound Leverage Factor	1.28	1.15	1.16	1.21	1.27	1.17	1.16	1.15	1.20
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	-49.09	-6.85	-6.66	-9.32	-11.46	-12.99	-16.77	-19.89	-30.83
Noncontrolling Interest Sharing Ratio	0.00%	0.18%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-
Current Ratio	2.72	12.73	13.02	7.13	5.81	4.35	4.47	7.60	20.86
Quick Ratio	2.43	12.37	12.40	6.64	5.54	4.15	4.09	6.79	20.17
Cash Flow Metrics	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	4.13	0.23	-6.38	-7.43	-6.47	-4.08	-2.93	-7.79	-8.52
Operating Cash Flow to CapEx	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-
Asset Turnover	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01
Accounts Receivable Turnover	0.98	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	4.75
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	371.70	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	371.70	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-
Invested Capital	-4.00	-4.57	-2.63	-3.28	-6.70	-9.43	-6.14	-0.77	-0.29
Invested Capital Turnover	1.43	-0.21	-0.13	-0.14	-0.09	-0.07	-0.14	-0.24	-0.14
Increase / (Decrease) in Invested Capital	-8.49	-5.01	1.22	0.15	-2.70	-4.86	-3.51	2.51	5.85
Enterprise Value (EV)	-2.25	-61	-43	-50	-43	-12	-26	-12	-5.02
Market Capitalization	13	33	43	29	28	49	24	27	20
Book Value per Share	$3.51	$6.36	$5.91	$5.15	$4.31	$3.53	$2.90	$2.33	$0.74
Tangible Book Value per Share	$3.51	$6.36	$5.91	$5.15	$4.31	$3.53	$2.90	$2.33	$0.74
Total Capital	12	89	83	75	64	52	44	39	25
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-16	-93	-86	-78	-70	-62	-50	-40	-25
Capital Expenditures (CapEx)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-4.44	-4.88	-2.71	-6.13	-9.36	-12	-7.65	-1.14	-0.38
Debt-free Net Working Capital (DFNWC)	11	88	83	72	61	50	43	39	25
Net Working Capital (NWC)	11	88	83	72	61	50	43	39	25
Net Nonoperating Expense (NNE)	2.22	1.41	1.08	2.13	2.99	3.08	2.17	0.48	0.91
Net Nonoperating Obligations (NNO)	-16	-93	-86	-78	-70	-62	-50	-40	-25
Total Depreciation and Amortization (D&A)	0.00	-0.26	-0.78	-0.62	-0.51	-0.54	-0.32	-0.21	-0.01
Debt-free, Cash-free Net Working Capital to Revenue	-1,254.24%	-1,151.42%	-640.90%	-1,260.29%	-1,898.17%	-2,374.85%	-1,264.46%	-239.50%	-82.60%
Debt-free Net Working Capital to Revenue	3,124.86%	20,854.95%	19,691.02%	14,819.34%	12,347.67%	9,903.79%	7,044.96%	8,089.71%	5,408.15%
Net Working Capital to Revenue	3,124.86%	20,854.95%	19,691.02%	14,819.34%	12,347.67%	9,903.79%	7,044.96%	8,089.71%	5,408.15%
Earnings Adjustments	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($2.01)	($0.60)	($0.15)	($0.22)	($0.29)	($0.28)	($0.20)	($0.13)	($0.08)
Adjusted Weighted Average Basic Shares Outstanding	3.28M	10.27M	42.58M	42.59M	42.59M	42.59M	42.67M	42.76M	42.77M
Adjusted Diluted Earnings per Share	($2.01)	($0.60)	($0.15)	($0.22)	($0.29)	($0.28)	($0.20)	($0.13)	($0.08)
Adjusted Weighted Average Diluted Shares Outstanding	3.28M	10.27M	42.58M	42.59M	42.59M	42.59M	42.67M	42.76M	42.77M
Adjusted Basic & Diluted Earnings per Share	$0.00	($0.60)	$0.00	$0.00	$0.00	($0.28)	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	13.96M	14.10M	14.53M	14.75M	14.75M	15.21M	16.66M	25.47M	33.35M
Normalized Net Operating Profit after Tax (NOPAT)	-4.36	-4.78	-5.17	-7.28	-9.16	-8.94	-6.44	-5.28	-2.67
Normalized NOPAT Margin	-3,827.89%	-6,291.71%	-5,271.43%	-3,675.35%	-7,573.31%	-10,641.67%	-3,187.08%	-7,651.30%	-3,106.05%
Pre Tax Income Margin	-5,325.44%	-8,093.42%	-6,368.37%	-4,744.95%	-10,047.11%	-14,297.62%	-4,258.91%	-8,328.99%	-4,168.60%
Debt Service Ratios	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Financials Breakdown Chart

VYNE Therapeutics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, VYNE Therapeutics' financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Over the last 10 years, VYNE Therapeutics' net income changed from -$4.61 million in 2015 to -$26.48 million in 2025, a change of 474.7%. See VYNE Therapeutics' forecast for analyst expectations on what's next for the company.

VYNE Therapeutics' total operating income in 2025 was -$29.75 million, based on the following breakdown:

Total Gross Profit: $570 thousand
Total Operating Expenses: $30.32 million

Over the last 10 years, VYNE Therapeutics' total revenue changed from $0.00 in 2015 to $570 thousand in 2025, a change of 57,000,000.0%.

VYNE Therapeutics' total liabilities were at $2.40 million at the end of 2025, a 83.8% decrease from 2024, and a 80.8% decrease since 2016.

In the past 9 years, VYNE Therapeutics' cash and equivalents has ranged from $4.03 million in 2016 to $57.56 million in 2020, and is currently $24.03 million as of their latest financial filing in 2025.

Over the last 10 years, VYNE Therapeutics' book value per share changed from 0.00 in 2015 to 1.09 in 2025, a change of 109.0%.

Related Companies

Financial statements for NASDAQ:VYNE last updated on 7/16/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

VYNE Therapeutics (VYNE) Financials

Financials Breakdown Chart

VYNE Therapeutics Financials - Frequently Asked Questions

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

VYNE Therapeutics (VYNE) Financials

Annual Income Statements for VYNE Therapeutics

Quarterly Income Statements for VYNE Therapeutics

Annual Cash Flow Statements for VYNE Therapeutics

Quarterly Cash Flow Statements for VYNE Therapeutics

Annual Balance Sheets for VYNE Therapeutics

Quarterly Balance Sheets for VYNE Therapeutics

Annual Metrics And Ratios for VYNE Therapeutics

Quarterly Metrics And Ratios for VYNE Therapeutics

Financials Breakdown Chart

VYNE Therapeutics Financials - Frequently Asked Questions

When does VYNE Therapeutics' fiscal year end?

How has VYNE Therapeutics' net income changed over the last 10 years?

What is VYNE Therapeutics' operating income?

How has VYNE Therapeutics' revenue changed over the last 10 years?

How much debt does VYNE Therapeutics have?

How much cash does VYNE Therapeutics have?

How has VYNE Therapeutics' book value per share changed over the last 10 years?

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools